Latest Regulatory Risk News

Block, Inc. reported a robust Q1 2026 with AI-powered productivity gains, strong Cash App and Square growth, and a $5 billion share buyback boost. Despite a GAAP net loss due to restructuring and legal costs, the fintech giant raised its full-year outlook, signaling confidence in its AI-led transformation.

Critical Resources Limited (ASX:CRR) has initiated a pro-rata entitlement offer of Loyalty Options priced at $0.001 each, aiming to raise $319,410 and potentially $2.56 million upon exercise. The offer underscores significant dilution and operational risks amid ongoing exploration and legal challenges.

Brazilian Critical Minerals (ASX: BCM) has locked in pre-approval under Australia’s R&D Tax Incentive for its Ema Rare Earth Project, including critical overseas activities in Brazil. This reduces regulatory uncertainty and supports funding efficiency for advancing the project’s development.

Sequoia Financial Group has called off the sale of its InterPrac subsidiary to Conquest Investment Partners, citing unmet conditions and changed circumstances that made completion unviable. The company will now explore alternative strategic paths for InterPrac.

Light & Wonder (ASX:LNW) posted modest revenue growth in 2025, driven by Gaming and iGaming segments, while SciPlay revenue dipped slightly. The company completed its Grover acquisition, settled a $128 million IP dispute with Aristocrat, and transitioned to a sole ASX listing.

Dimerix has completed adult patient recruitment in its Phase 3 ACTION3 trial for DMX-200, with a blinded review confirming the study remains statistically powered to demonstrate treatment efficacy. The company also appointed a new CFO and is negotiating up to US$50 million in non-dilutive funding.

Blackstone Minerals has cleared a key regulatory hurdle at its Mankayan Copper-Gold Project, lifting a Cease and Desist Order and initiating a Pre-Feasibility Study. The company also strengthened its board with mining veteran Mark Williams and reported a solid cash position of $14.6 million.

AdAlta has secured Australian manufacturing for its lead CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients. This move is a key step toward local clinical trials and boosts the therapy’s global commercial appeal.

Acrux pivots from generics to developing a Female Testosterone therapy for HSDD, leveraging FDA feedback and a strong US market opportunity.

PYC Therapeutics fortified its balance sheet by $600 million and progressed key RNA therapeutic trials in Q1 2026, setting the stage for pivotal clinical data and regulatory submissions.

Macro Metals’ subsidiary Macro Mining Services has landed an exclusive 36-month mining services contract with Metal Logic, supporting the rollout of innovative modular smelting technology in the East Pilbara. The first work package at Poondano Mine is set to start mid-2026, promising regional economic and Indigenous engagement benefits.

Newmont Corporation delivered a standout first quarter in 2026, reporting $3.3 billion net income and $3.1 billion free cash flow, while authorising an additional $6 billion share repurchase program after completing the previous one.